よむ、つかう、まなぶ。

MC plus(エムシープラス)は、診療報酬・介護報酬改定関連のニュース、

資料、研修などをパッケージした総合メディアです。


参考資料1-2: 令和3年度厚生労働科学特別研究事業「臨床研究法の見直しの審議における新たな課題・論点への対応策の確立のための研究」班 欧米での観察研究の取り扱い (9 ページ)

公開元URL https://www.mhlw.go.jp/stf/newpage_24643.html
出典情報 厚生科学審議会 臨床研究部会(第29回 3/24)《厚生労働省》
低解像度画像をダウンロード

資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。

A.1. Is it a substance (ii) or
combination of substances
presented as having properties
for treating or preventing disease in
human beings?
A.2. Does the substance function as
a medicine? i.e. can it be
administered to human beings either
with a view to restoring, correcting or
modifying physiological functions by
exerting a pharmacological,
immunological or metabolic action or
to making a medical diagnosis or is
otherwise administered for a
medicinal purpose?
A.3.Is it an active substance in a
pharmaceutical form?

B.1. Are you only administering
any of the following substances?
* Human whole blood(iii);
* Human blood cells;
* Human plasma;
* A food product (iv) (including
dietary supplements) not
presented as a medicine;
* A cosmetic product(v)
* A medical device

C.1. To discover or verify/compare its
clinical effects?
C.2. To discover or verify/compare its
pharmacological effects, e.g.
pharmacodynamics?
C.3. To identify or verify/compare its
adverse reactions?
C.4. To study or verify/compare its
pharmacokinetics, e.g., absorption,
distribution, metabolism or excretion?

D.1. To ascertain or verify/compare
the efficacy(vi) of the medicine?
D.2. To ascertain or verify/compare
the
safety of the medicine?

(i) Cf. Article 1(2) of Directive 2001/83/EC, as amended
(ii) Substance is any matter irrespective of origin e.g. human, animal, vegetable or chemical that is being administered to a human being.
(iii) This does not include derivatives of human whole blood, human blood cells and human plasma that involve a manufacturing process.
(iv) Any ingested product which is not a medicine is regarded as a food. A food is unlikely to be classified as a medicine unless it contains one or more ingredients generally regarded as medicinal
and indicative of a medicinal purpose.
(v)The Cosmetic Directive 76/768/EC, as amended harmonises the requirements for cosmetics in the European Community. A "cosmetic product "means any substance or preparation intended
for placing in contact with the various external parts of the human body (epidermis, hair system, nails, lips and external genital organs) or with the teeth and mucous membranes of the oral cavity
with the view exclusively or principally to cleaning them, perfuming them or protecting them in order to keep them in good condition, change their appearance or correct body odours.
(vi) Efficacy is the concept of demonstrating scientifically whether and to what extent a medicine is capable of diagnosing, preventing or treating a disease and derives from EU pharmaceutical
legislation.
(vii) Assignment of patients to a treatment group by randomisation planned by a clinical trial protocol cannot be considered as current practice

9